GenScript Biotech and T-MAXIMUM Biotech have formed a strategic collaboration agreement to advance the development of T-MAXIMUM's CAR-T cell therapy using GenScript's CRISPR nucleic acid reagents.
This collaboration between GenScript Biotech and T-MAXIMUM Biotech represents a concerted effort to leverage each other's strengths and expertise in order to expedite the development of innovative CAR-T cell therapy solutions for patients, especially those with solid tumours.
This partnership entails GenScript providing various CRISPR reagents to T-MAXIMUM Biotech, which will assist in the entire process of developing universal CAR-T products, from the initial discovery phase to eventual commercialisation.
This collaboration is expected to streamline the regulatory procedures both in China and the United States, facilitating quicker progress of T-MAXIMUM's product pipeline and subsequently benefiting patients in need at an earlier timeframe.
The focus of the collaboration is on utilising R&D-to-GMP-level sgRNA to bolster the development of UCAR-T products targeting solid tumours. While CAR-T therapies have shown promising results in treating haematological tumours, addressing the significant challenges associated with solid tumours is crucial for further advancements in the field of cell-based therapies.
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions! Learn More!